Market Snapshot and Recent Performance
Gossamer Bio (ticker GOSS) experienced a notable surge of 13.64 % during the 24‑hour window that concluded at 01:27 AM Central Europe on Thursday, 22 March 2026. At the close of that period, the stock was trading at approximately USD 9.79 on major exchanges, reflecting a significant uptick from its previous close. With a circulating supply of roughly 6.1 million shares, the company’s market capitalisation sits at USD 51.6 million.
During the same 24‑hour span, trading volume amounted to roughly USD 2 million, indicating a modest but active liquidity level. Despite the recent rally, Gossamer’s performance over the past month remains negative, with a decline of 15.07 % since the end of February. The stock’s simple moving average (SMA) over the last 200 days is USD 48.95, a figure that highlights the current price’s substantial departure from longer‑term support levels.
Historical reference points underline the volatility of the share price: the 52‑week high was USD 309.60 on 15 December 2025, while the 52‑week low fell to USD 8.29 on 20 October 2026. These extremes demonstrate the dramatic swings that can occur in the biopharmaceutical sector, especially for companies engaged in cutting‑edge research and development.
Comparative Performance of Peer Companies
To contextualise Gossamer’s recent movements, the following table summarises how several related stocks performed over the same 24‑hour period:
| Company | Ticker | 24‑Hour Change | Current Price (USD) | Market Capitalisation (USD) |
|---|---|---|---|---|
| Nomad Power | NMAD | –0.27 % | 3.53 | 60.1 million |
| Xbiotech | XBIT | +1.00 % | 1.99 | 61.0 million |
| Hour Loop | HOUR | –2.82 % | 1.57 | 59.8 million |
| Genasys | GNSS | +0.76 % | 1.29 | 60.1 million |
| Biomea Fusion | BMEA | –11.96 % | 0.69 | 60.6 million |
While Gossamer Bio’s upward momentum stands out, the peer group presents a mixed picture. Xbiotech and Genasys exhibited modest gains, whereas Nomad Power, Hour Loop, and especially Biomea Fusion experienced declines. These variations underscore the differential risk profiles and market perceptions within the biopharmaceutical and related technology sectors.
Company Overview
Gossamer Bio, Inc. is a biopharmaceutical enterprise headquartered in San Diego, United States. The company’s core mission is the identification, acquisition, and development of therapeutic agents targeting immunology, inflammation, and oncology. By focusing on these high‑impact disease areas, Gossamer seeks to address unmet medical needs through innovative drug discovery and development pipelines.
Key corporate facts include:
- Industry: Health Care / Biopharmaceuticals
- Headquarters: San Diego, United States
- IPO Date: 8 February 2019
- Stock Exchange: Nasdaq
- Website: www.gossamerbio.com
Gossamer’s operational strategy emphasizes partnership and acquisition, allowing it to leverage external expertise and assets while maintaining a streamlined internal development process. The company serves a nationwide customer base, aiming to bring new therapeutics to the global market.
Bottom Line
Gossamer Bio’s recent 13.64 % rally signals a temporary reversal of its broader monthly decline and places the share price well below its 200‑day moving average. Investors should weigh this short‑term uptick against the company’s longer‑term trajectory, historical volatility, and the performance of peer firms within the sector. Continued monitoring of Gossamer’s pipeline progress, regulatory milestones, and market reception will be essential for assessing the sustainability of its recent gains.
